Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
-$0.26 today
- Market cap
- $618.50M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
Volume 1.18M
Average 1.27M
OLMA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Olema Pharmaceuticals, Inc.NASDAQ: OLMA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $49.23M rose 60.8% year over year, ahead of the +40.8% change in trailing-twelve-month research & development. Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +24.2% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +60.8% holds above the trailing-twelve-month pace of +40.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 157.7M USD
- Year-over-year change
- +26.6%
- 4-year CAGR
- +32.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 157.7M | +26.6% |
| FY2024 | 2024-12-31 | 124.52M | +44.6% |
| FY2023 | 2023-12-31 | 86.14M | +4.7% |
| FY2022 | 2022-12-31 | 82.27M | +61.0% |
| FY2021 | 2021-12-31 | 51.1M | — |
Research & Development vs competitors
How OLMA compares with its peers on the latest reported figures
- OLMA's LTM Mar 2026 research & development of $176.31M is the highest of the 2 companies compared; the peer median is $68M.
- Its year-over-year change of +40.8% is the highest of 2, against a peer median of +23.2%.
- Over three fiscal years its annual growth of +24.2% compares with a peer median of +5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $176.31M | +40.8% | +24.2% | — | |
| LTM Mar 2026 | $68M | +23.2% | +5.9% | 29.9% | |
| Peer median (excluding OLMA) | $68M | +23.2% | +5.9% | 29.9% | |
Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 51.1M | 82.27M | 86.14M | 124.52M | 157.7M |
| Selling, General & Admin | 20.39M | 24.71M | 18.82M | 17.74M | 21M |
| Operating Expenses | 71.49M | 106.99M | 104.96M | 142.26M | 178.7M |
| Depreciation & Amortization | 163K | 357K | 377K | 393K | 490K |
| EBITDA | (70.93M) | (104.43M) | (96.28M) | (129.08M) | (161.96M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (71.49M) | (106.99M) | (104.96M) | (142.26M) | (178.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 442K | 2.23M | 8.32M | 12.68M | 16.22M |
| Interest Expense | — | 0 | — | 0 | 0 |
| Other Income / Expenses | 395K | 2.2M | 8.31M | 12.78M | 16.25M |
| Income Before Tax | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.62) | (2.14) | (2.20) | (1.87) |
| EPS (Diluted) | (1.79) | (2.62) | (2.14) | (2.20) | (1.87) |
| Weighted Avg Shares | 39.52M | 40M | 45.25M | 58.74M | 87.01M |
| Weighted Avg Shares (Diluted) | 39.52M | 40M | 45.25M | 58.74M | 87.01M |
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
Intrinsic Alpha fair value
Locked
Current Price
$7.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.